Lexeo Therapeutics Inc (LXEO)

Currency in USD
3.025
+0.075(+2.54%)
Real-time Data·
Advertisement
LXEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.8653.210
52 wk Range
2.55010.990
Key Statistics
Prev. Close
2.95
Open
2.93
Day's Range
2.865-3.21
52 wk Range
2.55-10.99
Volume
804.3K
Average Volume (3m)
1.94M
1-Year Change
-66.7217%
Book Value / Share
2.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LXEO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.111
Upside
+730.12%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Lexeo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.111
(+730.12% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Buy42.00+1,288.43%24.00Maintain16/11/2026
Cantor Fitzgerald
Buy---Maintain16/11/2026
Stifel
Buy17.00+461.98%-Maintain16/11/2026
Cantor Fitzgerald
Buy35.00+1,057.02%-Maintain12/11/2026
Oppenheimer
Buy20.00+561.16%-Maintain02/11/2026

Lexeo Therapeutics Inc SWOT Analysis


Gene Therapy Pionee
Lexeo Therapeutics leads in rare cardiac diseases and Alzheimer's with innovative AAVrh10-based gene therapies, targeting high-impact medical needs
Pipeline Potential
Explore Lexeo's three key programs: LX2006 for Friedreich's Ataxia, LX2020 for PKP2-ACM, and LX1001 for Alzheimer's, with crucial data expected in 2024
Regulatory Landscape
Learn how Lexeo navigates a favorable FDA environment, potentially streamlining development through single-arm trials and flexible approval pathways
Market Outlook
Analyst price targets range from $24 to $28, reflecting optimism despite current market volatility and the speculative nature of gene therapy investments
Read full SWOT analysis

Lexeo Therapeutics Inc Earnings Call Summary for Q3/2026

  • Lexeo shares surged 18.47% to $3.40 after LX2020 showed 80% mean reduction in arrhythmia burden in high-dose HEROIC-PKP2 study cohort.
  • FDA indicated openness to guideline-defined NSVT as surrogate endpoint for accelerated approval, strengthening regulatory pathway for gene therapy.
  • Company holds approximately $220M cash, supporting pivotal study launch planned for second half of 2027 with 60-80 patients enrolled.
  • No revenue or EPS reported; portfolio prioritization update expected early 2027 to guide capital allocation across pipeline including Mantle assets.
  • Safety profile remained favorable with no new treatment-related serious adverse events; 71% of high-dose patients reported symptom improvement.
Last Updated: 16/11/2026, 14:06
Read Full Transcript

Earnings

Latest Release
16/11/2026
EPS / Forecast
-0.43 / -0.79
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare LXEO to Peers and Sector

Metrics to compare
LXEO
Peers
Sector
Relationship
P/E Ratio
−2.4x−4.6x−0.2x
PEG Ratio
−0.05−0.130.00
Price/Book
1.2x6.5x2.6x
Price / LTM Sales
-950.3x2.7x
Upside (Analyst Target)
-174.1%69.6%
Fair Value Upside
Unlock3.8%11.7%Unlock

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
17.09M20.83%50.42M
Other Institutional Investors
109.56M79.17%323.20M
Public Companies & Retail Investors
0.000.00%0.00
Total
126.65M100.00%373.62M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Montanova Capital, LLC7.78%6,384,20018,833
Affinity Asset Advisors, LLC7.08%5,807,61117,132

People Also Watch

0.7482
AMOD
-4.43%
1.4100
NXL
-1.40%
7.101
EVMN
+3.20%
4.025
PEPG
+5.09%

FAQ

What Is the Lexeo Therapeutics (NASDAQ: LXEO) Share Price Today?

The Lexeo Therapeutics stock price today is 3.025 USD.

What Stock Exchange Does Lexeo Therapeutics (LXEO) Trade On?

Lexeo Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Lexeo Therapeutics?

The stock symbol (also called a 'ticker') for Lexeo Therapeutics is "LXEO."

What Is the Current Lexeo Therapeutics Market Capitalisation?

As of today, Lexeo Therapeutics (NASDAQ: LXEO) market cap is 244.220M USD.

What Is Lexeo Therapeutics's (LXEO) Earnings Per Share (TTM)?

The Lexeo Therapeutics EPS is currently -1.27 (Trailing Twelve Months).

Is LXEO a Buy or Sell From a Technical Analyst Perspective?

Based on today's Lexeo Therapeutics moving averages and other technical indicators, the daily buy/sell signal for LXEO stock is Strong Sell.

How Many Times Has Lexeo Therapeutics Stock Split?

Lexeo Therapeutics has split 0 times. (See the LXEO stock split history page for full effective split date and price information.)

How Many Employees Does Lexeo Therapeutics Have?

Lexeo Therapeutics has 68 employees, based on their latest Companies House report.

What is the current trading status of Lexeo Therapeutics (NASDAQ: LXEO)?

As of 19/11/2026, Lexeo Therapeutics (LXEO) is trading at a share price of 3.025 USD, with a previous close of 2.950 USD. The stock has fluctuated within a day range of 2.865 USD to 3.210 USD, while its 52-week range spans from 2.550 USD to 10.990 USD.

What Is Lexeo Therapeutics (LXEO) Price Target According to Analysts?

The average 12-month price target for Lexeo Therapeutics is 25.111 USD, with a high estimate of 42 USD and a low estimate of 9 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +730.12% Upside potential.

What Is the LXEO Premarket Price?

LXEO's last pre-market stock price is 2.880 USD. The pre-market share volume is 16,740.000, and the stock has decreased by -0.070, or -2.370%.

What Is the LXEO After Hours Price?

LXEO's last after hours stock price is 3.000 USD, the stock has decreased by 0.050, or 1.690%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.